BACKGROUND: Thymoma is frequently associated with paraneoplastic diseases (PDs), most commonly with myasthenia gravis (MG). This association is thought to depend on thymoma's capacity to produce and export T lymphocytes. OBJECTIVE: (1) To determine the frequency and characteristics of thymoma-associated PDs other than MG; (2) to evaluate T cell maturation in thymomas with and without PDs. METHODS: We studied 260 patients with thymoma (associated with MG in 228). The occurrence of PDs was monitored together with the tumor outcome. Phenotypic characterization of thymocyte subsets in 14 thymoma samples (7 with and 7 without MG) was performed by FACS. RESULTS: A total of 47 PDs was diagnosed in 41/260 patients (15.8 %). Neurological PDs included neuromyotonia, limbic encephalitis, polymyositis, subacute hearing loss, psychosis and sleep disorders. A broad spectrum of nonneurological PDs were observed, among these, hematological and cutaneous diseases prevailed. Like MG, these disorders occurred either in the presence of the thymoma or at different times after thymomectomy; their onset often heralded a tumor recurrence. In thymomas from MG subjects, we found an increased proportion of fully mature CD4 single positive (SP) thymocytes and a reduced frequency of CD4SPCD25(+) cells; the latter finding may reflect a deficient generation of T regulatory cells, a reduced intratumorous activation of T cells, or both. CONCLUSIONS: We confirm the strong association of thymoma with PDs. These disorders often occurred in MG patients and their course in relation to thymoma was similar to that of MG. In accordance with previous observations, we found some alterations in the intratumorous production of mature CD4(+) T cells that could be involved in the pathogenesis of paraneoplastic autoimmunity.
BACKGROUND:Thymoma is frequently associated with paraneoplastic diseases (PDs), most commonly with myasthenia gravis (MG). This association is thought to depend on thymoma's capacity to produce and export T lymphocytes. OBJECTIVE: (1) To determine the frequency and characteristics of thymoma-associated PDs other than MG; (2) to evaluate T cell maturation in thymomas with and without PDs. METHODS: We studied 260 patients with thymoma (associated with MG in 228). The occurrence of PDs was monitored together with the tumor outcome. Phenotypic characterization of thymocyte subsets in 14 thymoma samples (7 with and 7 without MG) was performed by FACS. RESULTS: A total of 47 PDs was diagnosed in 41/260 patients (15.8 %). Neurological PDs included neuromyotonia, limbic encephalitis, polymyositis, subacute hearing loss, psychosis and sleep disorders. A broad spectrum of nonneurological PDs were observed, among these, hematological and cutaneous diseases prevailed. Like MG, these disorders occurred either in the presence of the thymoma or at different times after thymomectomy; their onset often heralded a tumor recurrence. In thymomas from MG subjects, we found an increased proportion of fully mature CD4 single positive (SP) thymocytes and a reduced frequency of CD4SPCD25(+) cells; the latter finding may reflect a deficient generation of T regulatory cells, a reduced intratumorous activation of T cells, or both. CONCLUSIONS: We confirm the strong association of thymoma with PDs. These disorders often occurred in MG patients and their course in relation to thymoma was similar to that of MG. In accordance with previous observations, we found some alterations in the intratumorous production of mature CD4(+) T cells that could be involved in the pathogenesis of paraneoplastic autoimmunity.
Authors: Philipp Ströbel; Andreas Rosenwald; Niklas Beyersdorf; Thomas Kerkau; Olaf Elert; Astrid Murumägi; Niko Sillanpää; Pärt Peterson; Vera Hummel; Peter Rieckmann; Christof Burek; Berthold Schalke; Wilfred Nix; Reinhard Kiefer; Hans Konrad Müller-Hermelink; Alexander Marx Journal: Ann Neurol Date: 2004-12 Impact factor: 10.422
Authors: Y Kadota; M Okumura; S Miyoshi; S Kitagawa-Sakakida; M Inoue; H Shiono; Y Maeda; T Kinoshita; R Shirakura; H Matsuda Journal: Clin Exp Immunol Date: 2000-07 Impact factor: 4.330
Authors: John Newsom-Davis; Camilla Buckley; Linda Clover; Ian Hart; Paul Maddison; Erdem Tüzüm; Angela Vincent Journal: Ann N Y Acad Sci Date: 2003-09 Impact factor: 5.691
Authors: M Chilosi; A Iannucci; L Fiore-Donati; G Tridente; M Pampanin; G Pizzolo; M Ritter; M Bofill; G Janossy Journal: J Neuroimmunol Date: 1986-05 Impact factor: 3.478
Authors: Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox Journal: PLoS Med Date: 2006-07 Impact factor: 11.069
Authors: Arun Rajan; Corey A Carter; Arlene Berman; Liang Cao; Ronan J Kelly; Anish Thomas; Sean Khozin; Ariel Lopez Chavez; Isabella Bergagnini; Barbara Scepura; Eva Szabo; Min-Jung Lee; Jane B Trepel; Sarah K Browne; Lindsey B Rosen; Yunkai Yu; Seth M Steinberg; Helen X Chen; Gregory J Riely; Giuseppe Giaccone Journal: Lancet Oncol Date: 2014-01-15 Impact factor: 41.316
Authors: Muhammad Rizwan Khawaja; Robert P Nelson; Nicholas Miller; Sunil S Badve; Elizabeth Loehrer; Magdalena Czader; Susan M Perkins; Kenneth Kesler; Patrick J Loehrer Journal: J Clin Immunol Date: 2012-01-08 Impact factor: 8.317